USX:MITPF - Mithra Pharmaceuticals SA Mithra Pharmaceuticals SA
Sector: Unknown, Industry: Unknown
Add to Watchlist
Add Alert 

Yahoo Finance (Live Price) Note: This stock seems to be inactive

USD 23.9    +0.0 (+0%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

15 Oct 2021



CEO: Mr. Leon Van Rompay

Headquarters: US

Employees: 300



Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for vasomotor menopausal symptoms relief; and PeriNesta, an oral treatment for perimenopause. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.